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White and brown adipose tissues (BATs), which store and burn lipids, respectively, play
critical roles in energy homeostasis. Fibroblast growth factors (FGFs) are signaling pro-
teins with diverse functions in development, metabolism, and neural function. Among 22
FGFs, FGF1, FGF10, and FGF21 play roles as adipokines, adipocyte-secreted proteins, in
the development and function of white and BATs. FGF1 is a critical transducer in white adi-
pose tissue (WAT) remodeling.The peroxisome proliferator-activated receptor γ–FGF1 axis
is critical for energy homeostasis. FGF10 is essential for embryonic white adipocyte devel-
opment. FGF21 activates BAT in response to cold exposure. FGF21 also stimulates the
accumulation of brown-like cells in WAT during cold exposure and is an upstream effec-
tor of adiponectin, which controls systemic energy metabolism. These findings provide
new insights into the roles of FGF signaling in white and BATs and potential therapeutic
strategies for metabolic disorders.
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INTRODUCTION
White adipose tissue (WAT), a lipid storage site, plays a critical role
in energy homeostasis. Obesity, the excessive development of WAT,
is a well-known risk factor for several diseases including diabetes,
hypertension, and atherosclerosis (1, 2). Brown adipose tissue
(BAT) burns lipids and dissipates chemical energy as protection
against hypothermia and obesity (3). Therefore,understanding the
molecular and cellular mechanisms of adipose tissue development
and metabolism has become a priority. WAT is also a dynamic tis-
sue that actively communicates by sending adipocyte-secreted pro-
teins,adipokines,which act in an autocrine/paracrine or endocrine
manner. This secretory function has been highlighted in relation
to adipose tissue development, remodeling, and metabolism (1,
2). Although BAT also produces adipokines, the endocrine roles
of BAT are needed to determine by further research (4).
Fibroblast growth factors (FGFs) are signaling proteins with
diverse functions in development, metabolism, and neural func-
tion. The FGF family comprises 22 members (5). Among these
FGFs, FGF1, FGF10, and FGF21 have been shown to play roles
as adipokines in WAT development, remodeling, and metabolism.
FGF21 also activates BAT as an adipokine. These findings provide
new insights into their roles in adipose tissues and provide poten-
tial therapeutic strategies for obesity and metabolic disorders. A
succinct review of the roles of FGFs as adipokines is provided in
this article.
THE FGF FAMILY
Fibroblast growth factors are proteins with ~150–300 amino acids
and a conserved core of ~120 amino acids (~30–60% identity).
Phylogenetic analysis of the Fgf gene family identifies seven sub-
families, indicating potential evolutionary relationships in this
gene family. FGFs are also classified as intracrine, paracrine,
and endocrine FGFs by their action mechanisms (Figure 1).
Intracrine FGFs, which are not secreted extracellularly, play
roles in the regulation of electrical excitability in neurons in
an intracrine manner. Paracrine FGFs, secreted FGFs, mediate
biological responses by binding to cell surface FGF receptors
(FGFRs) with heparin/heparan sulfate as a cofactor, which is nec-
essary for stable interactions with FGFRs and local signaling (5).
Seven major FGFR proteins (FGFRs 1b, 1c, 2b, 2c, 3b, 3c, and
4) with differing ligand-binding specificity are generated from
Fgfr1, Fgfr2, Fgfr3, and Fgfr4 genes by alternative splicing. FGF
binding to FGFRs induces the activation of four key intracellu-
lar signaling pathways: RAS–RAF–MAPK, PI3K–AKT, STAT, and
PLCγ (6). Endocrine FGFs also mediate their biological responses
in an FGFR-dependent manner. However, they do not require
heparin/heparan sulfate, which enables endocrine FGFs to func-
tion in an endocrine manner. α- and β-Klotho, single-pass trans-
membrane proteins with short cytoplasmic domains, are essential
for endocrine FGF signaling as cofactors (5, 7).
ADIPOKINES
White adipose tissue mainly comprises adipocytes. Preadipocytes,
adipocyte precursors cells, are also present in WAT. Adipogenesis
is the differentiation of preadipocytes to adipocytes. Expansion of
the adipose tissue mass is caused by a combination of size increases
in the pre-existing adipocytes and adipogenesis. Some adipokines,
adipocyte-secreted proteins including leptin and adiponectin play
roles in the regulation of appetite, food intake, and energy home-
ostasis in an endocrine manner. Other adipokines including
tumor necrosis factor α and interleukin-6 play roles in adi-
pose tissue remodeling, adipogenesis, and angiogenesis in an
autocrine/paracrine manner (1, 2). Secreted adipokines includ-
ing insulin-like growth factor 1 and interleukin-6 are produced in
BAT in response to cold exposure (4). FGF1, FGF10, and FGF21
also play roles as autocrine/paracrine adipokines in WAT or BAT.
www.frontiersin.org February 2014 | Volume 5 | Article 18 | 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ohta and Itoh Roles of FGFs as adipokines
FIGURE 1 | Evolutionary relationships within the Fgf gene family by
phylogenetic analysis. Phylogenetic analysis shows that 22 Fgf genes can
be arranged into seven subfamilies containing two to four members each.
Branch lengths are proportional to the evolutionary distance between each
gene (5).
FGF1
FGF1 is not a typical secreted protein and may be released from
damaged cells or in an exocytotic mechanism. FGF1 mediates bio-
logical responses by activating FGFRs. However, Fgf1 knockout
mice normally have no significant phenotype (5).
Fgf1 is highly induced in WAT by a high-fat diet. The nuclear
receptor peroxisome proliferator-activated receptor γ (PPARγ)
is the adipocyte master regulator and target of the thiazolidine-
dione class of insulin sensitizing drugs (8). FGF1 induction is
regulated by PPARγ. Fgf1 knockout mice develop an aggressive
diabetic phenotype coupled to aberrant adipose expansion by a
high-fat diet. In addition, they show multiple histopathologies in
the vasculature network, an accentuated inflammatory response,
and aberrant adipocyte size distribution. However, this inflamed
adipose tissue fails to resolve properly, resulting in extensive white
fat necrosis with the withdrawal of the high-fat diet (9). WAT
remodeling in nutrient availability is essential to maintain meta-
bolic homeostasis (10). These findings indicate that FGF1 is a
critical transducer in WAT remodeling and that the PPARγ–FGF1
axis is critical for maintaining metabolic homeostasis and insulin
sensitization. Although which FGFR mediates the FGF1 action
remains unclear, the axis provides the therapeutic potential of
FGF1 in potentially mediating insulin sensitization (Table S1 in
Supplementary Material).
FGF10
FGF10 is a paracrine FGF, for which FGFR2b is a specific recep-
tor. Fgf10 knockout mice die shortly after birth with impaired
multi-organ formation, which indicates that FGF10 is critical
for multi-organ formation (5). Thus, its roles at postnatal stages
remain unclear. Fgf10 is abundantly expressed in WAT, in which
Fgf10 is particularly expressed by preadipocytes. WAT develop-
ment with markedly less proliferative activity is greatly impaired
in Fgf10 knockout mouse embryos. The Ras/MAPK pathway, acti-
vated through FGFR2b by FGF10, is essential for its mitogenic
activity in preadipocytes (Figure 2A) (11, 12).
The retinoblastoma family proteins, pRb and p130, are involved
in the cell cycles of various cells. They bind to E2Fs in quiescent
cells, leading to the repression of target genes involved in the cell
cycle. When quiescent cells are stimulated to enter the cell cycle,
retinoblastoma family proteins are subjected to cyclin-dependent
phosphorylation to release E2Fs, which advance the cell cycle (13).
Cyclin D2 expression and p130 phosphorylation are impaired in
the WAT of Fgf10 knockout mouse embryos. FGF10 stimulates
cyclin D2 expression and p130 phosphorylation in cultured cells.
Thus, FGF10 stimulates cell proliferation through the activation
of FGFR2b and Ras/MAPK pathway, followed by the cyclin D2-
dependent phosphorylation of p130 in WAT (Figure 2A) (Table
S1 in Supplementary Material) (14).
Adipogenesis is the process by which preadipocytes differ-
entiate into mature adipocytes. The CCAAT/enhancer binding
protein α (C/EBPα) and PPARγ are required for adipogenesis.
Although Pparγ expression is markedly decreased in the WAT of
Fgf10 knockout mouse embryos, C/ebpα expression is essentially
unchanged. Pparγ expression is markedly reduced in the WAT
of C/ebpα knockout mice. However, Fgf10 expression is essen-
tially unchanged. In addition, Fgf10 and C/ebpα expression in the
WAT of wild-type embryos is followed by Pparγ expression (12).
The number of pRb-positive cells is markedly decreased in the
WAT of Fgf10 knockout mouse embryos, although pRb phospho-
rylation is not inhibited (14). pRb knockout fibroblasts do not
differentiate into adipocytes. In addition, pRb binds directly to
C/EBPs and stimulates the activity of C/EBPs (15). Thus, FGF10
induces pRb production by activating FGFR2b and the Ras/MAPK
pathway. pRb binds C/EBPα and induces the expression of Pparγ,
followed by the stimulation of adipogenesis (Figure 2A) (Table S1
in Supplementary Material) (14).
FGF21
FGF21 mainly acts as a hepatic endocrine regulator, a hepatokine,
in glucose and lipid metabolism. Hepatic Fgf21 expression is
markedly induced in mice by fasting or a ketogenic diet. The results
from experiments using Fgf21 transgenic mice and cultured cells
demonstrate that FGF21 exerts pharmacological effects on glucose
and lipid metabolism in hepatocytes and white adipocytes via cell
surface FGFRs. Fgf21 transgenic mice are resistant to diet-induced
obesity. Serum glucose levels are also reduced to near normal lev-
els in both ob/ob and db/db mice by the administration of FGF21.
These findings indicate that FGF21 plays a role in glucose metab-
olism and has potential therapeutic effects on metabolic diseases.
However, the results from experiments using Fgf21 knockout mice
reveal that FGF21 inhibits lipolysis in white adipocytes during
fasting and attenuates torpor induced by a ketogenic diet, but may
be not a physiological regulator for these hepatic functions. These
findings suggest that its pharmacological effects are distinct from
its physiological roles (16, 17).
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FIGURE 2 | Action mechanisms of FGF10 and FGF21. (A) FGF10 acts on
white preadipocytes in an autocrine/paracrine manner. The possible
mechanisms of FGF10-induced cell proliferation and adipogenesis in white
preadipocytes are shown (14). (B) FGF21 acts on white adipocytes in an
autocrine/paracrine manner. The possible mechanism of FGF21-induced
adiponectin production in white adipocytes is shown (25).
Brown adipose tissue expresses FGFR1c and β-Klotho, a strong
candidate receptor and co-receptor for FGF21 signaling, respec-
tively. Exogenous FGF21 activates BAT (18). Cold exposure
also activates β-adrenergic receptors on brown adipocytes. This
process induces mitochondrial uncoupling protein 1 (UCP1),
which releases chemical energy as heat by uncoupling oxidative
phosphorylation. The induction of co-activator PGC-1α by cold
exposure induces Ucp1 expression (3). In addition to secreted
adipokines including insulin-like growth factor 1 and interleukin-
6, which are produced in BAT in response to cold exposure (4),
FGF21 is also synthesized in BAT in response to cold exposure.
These findings indicate that FGF21 activates BAT as an adipokine
in an autocrine/paracrine manner (Table S1 in Supplementary
Material) (19).
In addition to BAT, UCP1-positive, brown fat-like cells can
emerge in WAT with prolonged cold exposure (20). The marked
accumulation of brown-like cells can be found most readily in sub-
cutaneous WAT. This process is characterized by the appearance
of UCP1-positive, multilocular adipocytes. WAT also expresses
Fgf21, Fgfr1c, and β-Klotho (18). Fgf21 knockout mice display
an impaired ability to adapt to chronic cold exposure, with
the diminished browning of WAT. FGF21 produced in WAT
increases the expression of Ucp1 and other thermogenic genes
in an autocrine/paracrine manner. FGF21 regulates this process,
at least in part, by enhancing adipose tissue PGC-1α protein lev-
els. These findings indicate that FGF21 activates the thermogenic
machinery to provide a robust defense against hypothermia (Table
S1 in Supplementary Material) (21).
In WAT, FGF21, which forms a feed-forward loop with PPARγ,
mediates the metabolic benefits of PPARγ on glucose homeosta-
sis and insulin sensitivity in an autocrine/paracrine manner (22).
In lipodystrophic mice with less WAT, systemic FGF21 administra-
tion is not effective in decreasing blood glucose levels or increasing
insulin sensitivity. However, FGF21 is effective after the transplan-
tation of WAT into these mice (23). These findings indicate that
WAT is a predominant site conferring the antidiabetic activities
of FGF21.
Adiponectin has many functional similarities to FGF21.
Adiponectin as an adipokine controls systemic glucose and lipid
homeostasis in the liver and skeletal muscle in an endocrine
manner. Furthermore, adiponectin is a downstream effector of
PPARγ and an essential mediator for many therapeutic bene-
fits of the PPARγ agonists TZDs, including insulin sensitization
and vascular protection (24). FGF21 enhances both the expres-
sion and secretion of adiponectin in white adipocytes and serum
levels of adiponectin in mice. Adiponectin knockout mice are
refractory to several therapeutic benefits of FGF21. Further-
more, the effects of FGF21 on the attenuation of obesity-induced
impairments in insulin signaling in the liver and skeletal mus-
cle are abrogated in adiponectin knockout mice. However, the
FGF21-mediated activation of ERK1/ERK2 in WAT remains unaf-
fected in adiponectin knockout mice. These findings indicate that
adiponectin couples FGF21 actions as a downstream effector of
FGF21 in white adipocytes and mediates the systemic effects
of FGF21 on energy metabolism and insulin sensitivity in the
liver and skeletal muscle (Figure 2B) (Table S1 in Supplementary
Material) (25, 26).
Insulin resistance arises from the aberrant accumulation
of intracellular lipids, including the sphingolipid ceramide, in
insulin-responsive tissues. FGF21 stimulates adiponectin secre-
tion and diminishes the accumulation of ceramides in obese
animals. Adiponectin knockout mice are refractory to changes
in energy expenditure and the ceramide-lowering effects evoked
by FGF21 administration (26). These findings indicate that an
FGF21–adiponectin–ceramide axis controls energy expenditure
and insulin action.
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CONCLUSION
Although WAT and BAT store and burn lipids, respectively, they
are also dynamic tissues that actively communicates by sending
different types of adipokines, which mainly play roles in energy
homeostasis. FGFs are signaling proteins with diverse functions
in development, metabolism, and neural function. In addition,
FGF1, FGF10, and FGF21 have been shown to be adipokines with
crucial roles in WAT or BAT functions, suggesting new roles for
FGFs and potential therapeutic strategies for metabolic disorders.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online
at http://www.frontiersin.org/Journal/10.3389/fendo.2014.00018/
abstract
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